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Abstract
Background: Mucormycosis (or zygomycosis) is the term for infection caused by fungi of the order
Mucorales. Mucoraceae may produce severe disease in susceptible individuals, notably patients with
diabetes and leukemia. Rhinocerebral mucormycosis most commonly manifests itself in the setting
of poorly controlled diabetes, especially with ketoacidosis.
Case Presentation: A 31-year-old diabetic man presented to the outpatient clinic with the
following signs and symptoms: headache, periorbital pain, swelling and loss of vision in the right eye.
On physical examination his right eye was red and swollen. There was periorbital cellulitis and the
conjunctiva was edematous. KOH preparation of purulent discharge showed broad, ribbonlike,
aseptate hyphae when examined under a fluorescence microscope. Cranial MRI showed
involvement of the right orbit, thrombosis in cavernous sinus and infiltrates at ethmoid and
maxillary sinuses. Mucormycosis was diagnosed based on these findings. Amphotericin B
(AmBisome®; 2 mg/kg.d) was initiated after the test doses. Right orbitectomy and right partial
maxillectomy were performed; the lesions in ethmoid and maxillary sinuses were removed. The
duration of the liposomal amphotericin B therapy was approximately 6 months and the total dose
of liposomal amphotericin B used was 32 grams. Liposomal amphotericin B therapy was stopped
six months later and oral fluconazole was started.
Conclusions: Although a total surgical debridement of the lesions could not be performed, it is
remarkable that regression of the disease could be achieved with medical therapy alone.
Background
Mucormycosis (or zygomycosis) is the term for infection
caused by fungi of the order Mucorales [1–4]. Mucorace-
ae may produce severe disease in susceptible individu-
als, notably patients with diabetes and leukemia.
Rhinocerebral mucormycosis most commonly manifests
itself in the setting of poorly controlled diabetes, espe-
cially with ketoacidosis. The causative organism in most
cases is Rhizopus oryzae. Progression of the disease is
usually rapid, although it may become indolent if ketoac-
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idosis resolves. Because of the rapidity with which this
disease progresses, prompt and aggressive therapy is es-
sential [5–7]. Since the introduction of combined thera-
py with amphotericin B and surgery, more than 80% of
the patients can be expected to survive [6–8]. Adminis-
tration of amphotericin B is, however, associated with
adverse effects that may prevent maintenance of effec-
tive doses [9]. Because of this problem, amphotericin B
has been inserted into liposomes. When the drug is ad-
ministered in this form, adverse effects are less pro-
nounced, even with administration of larger doses
[10,11]. Recent work has suggested that the new antifun-
gal triazole, fluconazole may be of benefit in treating zy-
gomycete infection [2,3,12]. We described a case of
rhinocerebral mucormycosis which was treated with sur-
gery and a 6 month course of liposomal amphotericin B
(a total of 32 gr) followed by a course of fluconazole.
Case report
In August 1998, a 31-year-old diabetic man presented to
the outpatient clinic at the Department of Clinical Bacte-
riology and Infectious Diseases, Istanbul Faculty of Med-
icine, with the following signs and symptoms: headache,
periorbital pain, swelling and loss of vision in the right
eye. Two months prior, he had been admitted to another
hospital with headache and was diagnosed as paranasal
sinusitis. Despite antimicrobial therapy with ampicillin/
sulbactam, his condition had worsened i.e, headache be-
came more severe and the aforementioned signs and
symptoms related with the right eye appeared. The pa-
tient had not been compliant with insulin therapy. At the
time of admission, the patient was alert, and oriented.
He was afebrile, and his vital signs were stable. On phys-
ical examination, his right eye was red and swollen.
There was periorbital cellulitis, and the conjunctiva was
edematous. There was a purulent discharge coming from
the right orbit. Laboratory results were as follows; white
blood cells, 9 ×  103/mm3 with 86 % neutrophils, 13%
lymphocytes; hemoglobin, 12.4 gr/mm3; hematocrit,
36.5 %; plasma glucose, 446 mg/dl; blood urea nitrogen,
44 mg/dl; creatinine, 0.9 mg/dl; serum sodium, 130
mEq/dl; serum potassium, 3.3 mEq/dl; aspartate
transaminase, 38 U/L; alanine transaminase, 30 U/L;
ESR 98 mm/h; CRP 12 mg/dl. Glycosuria and acetonuria
were detected in urinalysis. Other biochemical results
were normal. Gram and KOH stain were performed on
the exudate obtained from the right eye. It was also inoc-
ulated onto blood agar, Mac Conkey agar, Sabouraud
agar as it is routinely done. KOH preparation showed
broad, ribbonlike, aseptate hyphae when examined un-
der a fluorescence microscope. Cranial MRI showed in-
volvement of the right orbit and optic nerve, thrombosis
in cavernous sinus and infiltrates at ethmoid and maxil-
lary sinuses (figure 1). Mucormycosis was diagnosed
based on these findings.
The blood glucose levels was controlled with regular in-
sulin. Amphotericin B (1 mg/kg.d) was initiated after the
test doses. Seven days later, this regimen was replaced
with liposomal amphotericin B (AmBisome®; 2 mg/
kg.d) due to increase of creatinine level and side effects
such as fever and chills. This resulted in normalization of
creatinine level and disappearence of the side effects. Af-
ter one week of this regimen, the dose of liposomal am-
photericin B was raised up to 4 mg/kg/day. During the
course of the treatment, the patient was closely moni-
tored for signs and symptoms of drug toxicity, and tests
for acute phase reactants (CRP, ESR) were performed.
Figure 1
Cranial MRI (transaxial section) at the level of the ethmoid
and maxillary sinuses showing contrast enhancement.
Figure 2
Cranial MRI after surgical debridementBMC Infectious Diseases 2001, 1:22 http://www.biomedcentral.com/1471-2334/1/22
After neurosurgical and otorhinolaryngological evalua-
tion, the patient apted to receive medical therapy alone.
Three months later, the patient was reevaluated. Because
there was no regression of the lesions previously noted
on MRI, the patient agreed to undergo surgery. Right or-
bitectomy, and right partial maxillectomy were per-
formed; the lesions in ethmoid and maxillary sinuses
were removed. The specimens obtained from sinuses
were intraoperatively examined under a fluorescence
microscope after treating the samples with KOH or fluo-
rescence conjugated antibody, broad, ribbonlike, and
aseptate hyphae were visualized.
Following surgery, liposomal amphotericin B was con-
tinued. His blood glucose levels were easily controlled.
Periorbital swelling and discharge gradually resolved.
One month after the surgery, new infiltrates within eth-
moid and maxillary sinuses as well as spread of infiltra-
tion to frontal sinuses and infiltration of fatty pad around
left orbit were detected. A partial surgical debridment
was accomplished. One month after this operation, infil-
trations were still present within ethmoid and maxillary
sinuses but not around left orbit. Liposomal amphoter-
icin B therapy (4 mg/kg/day) was maintained and two
months later, there was not any progression of the dis-
ease as indicated by the MRI (Figure 2). Liposomal am-
photericin B therapy was stopped in March 1999 (six
months later) and oral fluconazole (200 mg/d) was start-
ed based on the current medical literature [2,3,12]. Three
months after fluconazole therapy was started, the lesion
in the right cavernous sinus was partially resolved. De-
spite the decision to continue the oral fluconazole thera-
py, the patient refused it. A MRI performed four months
after the patient discontinued the treatment did not
show progression of the disease (Figure 3).
Conclusions
The duration of the therapy was approximately 6
months, and the total dose of liposomal amphotericin B
used was 32 grams. Although there has been previous re-
ports on the use of Amphotericin B in various prepara-
tions such as lipid complex or colloidal dispersion, with
a maximum total dose up to 73.6 grams in the treatment
of invasive fungal infections [13–15], our case report is
the first one in the literature where liposomal amphoter-
icin B was administered in such a high dose (total 32
grams) over such a long period, i.e, 6 months. No adverse
effect was detected during therapy. Creatinine and elec-
trolyte levels (especially potassium) remained within
normal ranges.
Although a total surgical debridement of the lesions
could not be performed, it is remarkable that regression
of the disease could be achieved with medical therapy
alone. We could not find any recommendation in the lit-
erature on the duration of liposomal amphotericin B and
use of fluconazole therapy. The optimal duration of anti-
fungal therapy depends on the response of infection to





Written consent was obtained from the patient or their relative for publi-
cation of the patient's details.
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